Aurinia Pharmaceuticals Inc (AUPH)
7.18
-0.11
(-1.51%)
USD |
NASDAQ |
Oct 04, 16:00
7.18
0.00 (0.00%)
After-Hours: 19:30
Aurinia Pharmaceuticals Enterprise Value: 694.84M for Oct. 3, 2023
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 03, 2023 | 694.84M |
| October 02, 2023 | 716.35M |
| September 29, 2023 | 763.68M |
| September 28, 2023 | 779.46M |
| September 27, 2023 | 793.80M |
| September 26, 2023 | 821.05M |
| September 25, 2023 | 812.44M |
| September 22, 2023 | 846.86M |
| September 21, 2023 | 835.39M |
| September 20, 2023 | 845.43M |
| September 19, 2023 | 876.98M |
| September 18, 2023 | 854.04M |
| September 15, 2023 | 917.14M |
| September 14, 2023 | 951.56M |
| September 13, 2023 | 958.73M |
| September 12, 2023 | 957.30M |
| September 11, 2023 | 1.043B |
| September 08, 2023 | 1.059B |
| September 07, 2023 | 1.039B |
| September 06, 2023 | 1.111B |
| September 05, 2023 | 1.055B |
| September 01, 2023 | 1.006B |
| August 31, 2023 | 950.13M |
| August 30, 2023 | 960.17M |
| August 29, 2023 | 963.04M |
| Date | Value |
|---|---|
| August 28, 2023 | 958.73M |
| August 25, 2023 | 963.04M |
| August 24, 2023 | 930.05M |
| August 23, 2023 | 980.25M |
| August 22, 2023 | 993.16M |
| August 21, 2023 | 1.019B |
| August 18, 2023 | 1.053B |
| August 17, 2023 | 1.010B |
| August 16, 2023 | 1.046B |
| August 15, 2023 | 1.023B |
| August 14, 2023 | 1.035B |
| August 11, 2023 | 1.012B |
| August 10, 2023 | 1.020B |
| August 09, 2023 | 1.006B |
| August 08, 2023 | 1.042B |
| August 07, 2023 | 1.048B |
| August 04, 2023 | 1.058B |
| August 03, 2023 | 1.164B |
| August 02, 2023 | 1.102B |
| August 01, 2023 | 1.147B |
| July 31, 2023 | 1.310B |
| July 28, 2023 | 1.408B |
| July 27, 2023 | 1.236B |
| July 26, 2023 | 1.239B |
| July 25, 2023 | 1.176B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
207.43M
Minimum
Dec 27 2022
4.000B
Maximum
Oct 29 2021
1.160B
Average
1.177B
Median
Enterprise Value Benchmarks
| Acasti Pharma Inc | 3.354M |
| Edesa Biotech Inc | 7.085M |
| Lexaria Bioscience Corp | 4.304M |
| Liminal Biosciences Inc | -- |
| Xenon Pharmaceuticals Inc | 1.612B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -11.49M |
| Revenue (Quarterly) | 41.49M |
| Total Expenses (Quarterly) | 57.66M |
| EPS Diluted (Quarterly) | -0.08 |
| Gross Profit Margin (Quarterly) | 96.23% |
| Profit Margin (Quarterly) | -27.70% |
| Earnings Yield | -6.96% |
| Normalized Earnings Yield | -6.964 |